LUPIN - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.2
| Stock Code | LUPIN | Market Cap | 99,983 Cr. | Current Price | 2,187 ₹ | High / Low | 2,249 ₹ |
| Stock P/E | 18.7 | Book Value | 596 ₹ | Dividend Yield | 0.55 % | ROCE | 21.9 % |
| ROE | 17.8 % | Face Value | 2.00 ₹ | DMA 50 | 2,115 ₹ | DMA 200 | 2,033 ₹ |
| Chg in FII Hold | 1.00 % | Chg in DII Hold | -0.98 % | PAT Qtr | 869 Cr. | PAT Prev Qtr | 2,128 Cr. |
| RSI | 58.9 | MACD | 8.85 | Volume | 13,28,675 | Avg Vol 1Wk | 8,98,035 |
| Low price | 1,774 ₹ | High price | 2,249 ₹ | PEG Ratio | 0.11 | Debt to equity | 0.04 |
| 52w Index | 86.9 % | Qtr Profit Var | 7.55 % | EPS | 126 ₹ | Industry PE | 29.2 |
📊 Analysis: Lupin is trading at 2,187 ₹, above both its 50 DMA (2,115 ₹) and 200 DMA (2,033 ₹), showing strong technical support. RSI at 58.9 indicates healthy momentum without being overbought, while MACD (8.85) confirms bullish sentiment. Intraday volume (13.3 lakh) is significantly higher than the weekly average (8.9 lakh), suggesting strong participation today. Fundamentals remain solid with ROE 17.8%, ROCE 21.9%, and EPS at 126 ₹, making it a favorable intraday candidate.
💰 Optimal Buy Price (Intraday): 2,180–2,190 ₹ (near support zone).
📈 Profit-Taking Levels: 2,210 ₹ (first resistance), 2,235 ₹ (secondary resistance).
⚠️ Stop-Loss / Loss Protection: 2,165 ₹ (below intraday support).
⏱️ If Already Holding: Exit if price fails to sustain above 2,210 ₹ with volume confirmation or if RSI dips below 55 intraday. Hold for extended gains only if momentum sustains above 2,235 ₹ with strong volume.
Positive
- 📈 Strong technicals: trading above both 50 DMA and 200 DMA.
- 📊 EPS at 126 ₹ supports valuation strength.
- 📉 Low debt-to-equity (0.04), strong balance sheet.
- 📈 FII holdings increased (+1.00%).
Limitation
- ⚠️ Sequential decline in PAT (2,128 Cr. → 869 Cr.).
- 📉 DII holdings decreased (-0.98%).
- 📊 PEG ratio at 0.11 indicates limited growth premium.
Company Negative News
- 📉 Quarterly profit down sharply compared to previous quarter.
- ⚠️ DII selling pressure may weigh on sentiment.
Company Positive News
- 📈 FII accumulation (+1.00%) supports investor confidence.
- 📊 EPS strength and dividend yield (0.55%) add stability.
Industry
- 🏭 Pharma sector PE at 29.2, Lupin trades at a discount (18.7).
- 📈 Sector supported by defensive demand and global healthcare trends.
Conclusion
⚖️ Lupin is a strong intraday candidate. Buy near 2,180–2,190 ₹ with stop-loss at 2,165 ₹. Profit booking can be considered at 2,210–2,235 ₹. Momentum indicators are favorable, supported by strong volume and bullish MACD. Traders should rely on volume confirmation before holding beyond 2,235 ₹.
Would you like me to also prepare a peer benchmarking overlay comparing Lupin with pharma peers like Sun Pharma, Dr. Reddy’s, and Cipla to highlight relative intraday strength?